pharmaphorum

📢 In today's newsletter presented by Eloise McLennan https://lnkd.in/dM6NhQnz 💉 Find out what RFK Jr said about vaccines in his first speech as HHS Secretary. 🧬 Biogen adds to its pipeline again, this time in epilepsy. 💥 Phase 2b trial throws the future of Supernus' novel antidepressant into doubt. 🔬 HIV protection with just two injections a year could be on the way in the US. 👩⚖️ Novo Nordisk's licensing deal for a blood pressure drug cost it dearly – and now it is claiming fraud. #newsoftheday #lifesciences

At #JPM2025, our editor spoke with Rick Stewart about combatting nicotine addiction in 2025 -- and why it resembles a game of Whac-A-Mole. Link to full interview in comments.

In today's newsletter presented by our own Deep Dive editor Eloise McLennan https://lnkd.in/dE3cVS7C - Shionogi adds another piece to its healthcare as a service (HaaS) model in Japan. - Rare skin disorder bullous pemphigoid has no approved targeted treatments - but that could soon change. - Four more drugs have failed to pass muster in a platform ALS trial – but it may be premature to write them off. - A biosimilar of one of the most widely-used fast-acting insulins is finally available in the US. - Should AIs be able to prescribe medicines? One US lawmaker thinks so. #newsoftheday #LifeSciences #AI #biosimilars #rarediseases

Our comprehensive 7-part Life Sciences Industry Report is now available! Featuring expert insights from Roche, Pfizer, Novartis, IQVIA and more, plus proprietary data analysis from EVERSANA across: - US & European markets - GLP-1s - AI - Digital Health - Oncology - Rare disease - Biosimilars & generics What's your biggest focus for 2025? Join the conversation below.

🎙️ In today's newsletter, presented by Eloise McLennan: https://lnkd.in/deVCNj_q Mass firings have started at the FDA and CDC. Learn more here. Valneva is facing the first competitor to its chikungunya vaccine in the US. Can GSK overtake Pfizer in the 5-in-1 meningococcal vaccines market? Can Ono change practice in rare disease TGCT with its new product Romvimza? Istesso's rheumatoid arthritis drug failed a phase 2b trial – but don’t write it off just yet. #newsoftheday #lifesciences

At #JPM2025, we talked to REGENXBIO's Steve Pakola, MD about the challenges of bringing gene and cell therapies to market. Check out the full interview at pharmaphorum (link in comments)

In 2025, as #biopharma companies embrace #AI-first, purpose-built solution #strategies to better serve #healthcareprofessionals and #patients. Magnolia's Tobias Kerschbaum, Mark Melton, and Jan Schulte predict the landscape ahead this year. https://lnkd.in/e8z4VqJ2